ALKS Stock - Alkermes Inc.

ALKS Stock Chart

ALKS Profile

Alkermes plc, a leading biopharmaceutical company, specializes in researching, developing, and commercializing innovative pharmaceutical products aimed at addressing critical unmet medical needs across various therapeutic areas globally. Operating primarily in the United States, Ireland, and internationally, Alkermes is recognized for its robust portfolio of marketed products. These include ARISTADA, an injectable suspension used for treating schizophrenia, along with ARISTADA INITIO, designed to provide rapid treatment initiation for adult patients with schizophrenia. Additionally, the company offers VIVITROL, utilized for alcohol and opioid dependence prevention, and RISPERDAL CONSTA, targeting schizophrenia and bipolar I disorder management.

Alkermes plc is actively advancing its pipeline with promising candidates like LYBALVI, an oral atypical antipsychotic for adults dealing with schizophrenia and bipolar I disorder. Another significant development is nemvaleukin alfa, an engineered fusion protein that aims to enhance tumor-killing immune cells while preventing the activation of immunosuppressive cells. The company collaborates extensively, including key partnerships with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc., and Janssen Pharmaceutica International, leveraging synergies to drive innovation and expand therapeutic capabilities.

Founded in 1987 and headquartered in Dublin, Ireland, Alkermes plc has established itself as a pivotal player in the biopharmaceutical landscape. With a commitment to scientific excellence and patient-centric innovation, the company continues to pioneer advancements in mental health treatments and beyond, ensuring its products make a meaningful impact on patient lives worldwide.

ALKS Revenue Chart

ALKS Earnings

Analyst Ratings